Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATX-295 · 1 trial · 5 indications
Identification of a tolerable and safe dose for expansion cohorts based on dose limiting toxicities
Adverse events graded according to CTCAE v5.0
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Subjects will be enrolled at various doses and/or schedules of ATX-295 to identify the expansion dose(s) and RP2D |
| Dose Expansion: Platinum-Resistant, -Refractory, or -Intolerant HGSOC | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ATX-295 | DRUG | ATX-295 Tablets will be taken orally |
Key Inclusion Criteria: * Patients with histologically confirmed solid tumors who have locally recurrent or metastatic disease, including HGSOC * Refractory to or relapsed after all standard therapies with proven clinical benefit, unless as deemed by the Investigator, the subject is not a candidate...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |